Abstract: [Problem] The present invention addresses the problem of providing a compound that is useful for preventing or treating diseases associated with malfunctioning of PGI2 receptors, in particular, pulmonary hypertension. [Solution] A positive allosteric regulator of a PGI2 receptor which comprises a compound represented by formula (1) or a pharmaceutically acceptable salt, hydrate or solvate thereof. (1) (In the formula, R1 is a branched chain or cyclic alkyl or alkenyl having 3 to 10 carbon atoms which may be substituted, R2 is a hydrogen atom or an alkyl having 1 to 6 carbon atoms which may be substituted, R3 is 1 to 4 substituents which are the same or different independently selected from the group consisting of a hydrogen atom, a halogen atom, an alkyl having 1 to 6 carbon atoms which may be substituted, and an alkoxy having 1 to 6 carbon atoms which may be substituted, and A is an aryl which may be substituted or a heteroaryl which may be substituted.

Abstract: A brain cooling apparatus is provided that can circulate a fluid between a containing unit of a brain cooling device and the brain cooling apparatus while maintaining an appropriate pressure of the fluid in the containing unit, and a brain cooling device suitable thereto also is provided. A control device circulates a physiological saline solution between a storage tank and a cuff by driving a first pump in a direction in which the physiological saline solution flows toward the cuff, and driving a second pump in a direction in which the physiological saline solution flows toward the storage tank. In this state, the control device adjusts the rotation speed of at least the second pump, so that the pressure of the physiological saline solution in the cuff becomes a preset target pressure.

Abstract: The present invention provides compounds belonging to 3-acyloxyindole compounds or 3-acyl-4-hydroxycoumarin compounds, a tautomer or geometric isomer thereof, or a salt thereof and methods for producing the same, which compounds are useful as antibacterial agent and as therapeutic drugs against infectious diseases.

Abstract: The present invention provides a therapeutic agent, a treatment method and an inspection method for diseases caused by activation of neutrophils. More specifically, the invention relates to a neutrophil activation regulator which comprising a histidine-rich glycoprotein (HRG) as an active ingredient, and provides a therapeutic agent for diseases caused by neutrophil activation comprising the neutrophil activation regulator, a treatment method for diseases caused by neutrophil activation, and further an inspection method for diseases caused by neutrophil activation. The present invention is based on the neutrophil activation regulator including the HRG as an active ingredient. The present invention extends to the depressant agent for neutrophil-vascular endothelial cell interaction including the HRG of the present invention as an active ingredient, the treatment method for diseases caused by neutrophil activation and/or inflammatory diseases accompanied by neutrophil activation.

Abstract: An object of the present invention is to provide a method for increasing the expression of foreign genes, in particular, using a promoter, an enhancer, and the like, and an expression cassette containing a promoter, an enhancer, and the like, by which gene expression can be increased. The purpose is achieved with the use of the gene expression cassette comprising a DNA construct containing a gene to be expressed and a poly A addition sequence that are located downstream of a 1st promoter, and further comprising an enhancer or a 2nd promoter ligated downstream of the DNA construct.

Abstract: A kit for bonding to biological hard tissues, containing a phosphorylated polysaccharide, a polyvalent metal salt other than phosphates, and a solvent. The adhesive composition for biological hard tissues provided by the kit for bonding to biological hard tissues is suitably used in for medical uses, such as cement for bones or dental cement.

Abstract: Disclosed is a plant protection agent comprising an amorphous and/or microcrystalline silicon- and phosphorus-containing iron oxide, and a method for controlling plant diseases, comprising the step of applying the plant protection agent.

Abstract: In order to reduce the side effects of paclitaxel derivatives having excellent anti-cancer effects, an attempt was made to produce a liposome encapsulating paclitaxel derivatives such as paclitaxel monoglycosides and docetaxel monoglycosides. However, the introduction efficiency of paclitaxel derivatives, etc., into a liposome was poor, and this technique was not developed to a practical level. The present invention provides a method for producing a liposome encapsulating a paclitaxel monoglycoside and/or a docetaxel monoglycoside, and having an antibody specifically recognizing a cancer cell, the method comprising a step of bringing a liposome encapsulating a polyoxyethylene ester derivative, a lower alcohol, and a buffer or water into contact with a solution in which a paclitaxel monoglycoside and/or a docetaxel monoglycoside is dissolved in an alkylene glycol-containing buffer or water.

Abstract: A printed wiring board includes a digital circuit, an analog circuit, and a power supply path that is disposed on an insulating layer between the digital circuit and the analog circuit. EBG unit cells are disposed on a boundary between the digital circuit and the analog circuit one dimensionally or two dimensionally and periodically, and an interdigital electrode is formed. A magnetic body film is formed over the printed wiring board, partially formed on the EBG unit cells, or formed avoiding the EBG unit cells.

Abstract: Provided is a therapeutic agent for a disease accompanied by epileptiform discharges, which is easily-handled, has a low side effect, and has a fast acting property. By controlling the concentration of carbon dioxide of inhaled air, it is possible to change the pH in body fluids to an acidic side to reduce epileptiform discharges. Carbon dioxide is an active ingredient of a therapeutic agent for a disease accompanied by epileptiform discharges.

Abstract: A printed wiring board includes a digital circuit, an analog circuit, and a power supply path that is disposed on an insulating layer between the digital circuit and the analog circuit. A plurality of open stub EBG structures are disposed at an end of a bridge section in a power supply plane. The open stub EBG structure is an open stub state whose one end is connected to the power supply path and other end is in an open state.

Abstract: The present invention provides a neutrophil activation regulator comprising a histidine-rich glycoprotein (HRG) for the treatment of systemic inflammatory response syndrome (SIRS), diseases caused by neutrophil activation and/or inflammatory diseases accompanied by neutrophil activation in a subject in need thereof. Further, the present invention provides methods for predicting the severity of systemic inflammatory response syndrome (SIRS), diseases caused by neutrophil activation and/or inflammatory diseases accompanied by neutrophil activation in a subject in need thereof, and methods for predicting the survival of a subject with systemic inflammatory response syndrome (SIRS), diseases caused by neutrophil activation and/or inflammatory diseases accompanied by neutrophil activation, that comprise determining the blood level of histidine-rich glycoprotein in the subject.

Abstract: Provided is a novel anti-HCV agent including as an active ingredient a peroxide derivative represented by the general formula (I). In the general formula (I), C represents an alicyclic hydrocarbon ring group which may be substituted, n represents an integer of from 1 to 6, and R represents a hydrogen atom or a hydroxyalkyl group. The peroxide derivative exhibits potent anti-HCV activity by remarkably suppressing HCV-RNA replication.

Abstract: The present invention aims to provide an anti-Alzheimer's disease agent based on an action mechanism associated with amyloid ? protein, which action mechanism is different from conventional action mechanisms. The therapeutic drug for Alzheimer's disease according to the present invention contains a therapeutic agent for cognitive impairment induced by amyloid ? protein, which therapeutic agent comprises a peptide having the amino acid sequence represented by SEQ ID NO:1 or a peptide similar to this peptide, especially a peptide containing the amino acid sequence represented by SEQ ID NO:2, which is a partial sequence of SEQ ID NO:1.

Abstract: A kit for bonding to biological hard tissues, containing a phosphorylated polysaccharide, a polyvalent metal salt other than phosphates, and a solvent. The adhesive composition for biological hard tissues provided by the kit for bonding to biological hard tissues is suitably used in for medical uses, such as cement for bones or dental cement.

Abstract: An objective of the present invention is to provide an adenovirus vector expressing a REIC/Dkk-3 protein at a high level and containing a DNA construct for expression of REIC/Dkk-3 DNA, wherein the DNA construct is prepared by ligating, from the 5? terminal side, (i) a CMV promoter, (ii) REIC/Dkk-3 DNA, (iii) a polyA addition sequence, and (iv) enhancers prepared by linking an hTERT (Telomerase Reverse Transcriptase) enhancer, an SV40 enhancer, and a CMV enhancer in this order.

Abstract: [Problem] To provide: a bactericidal agent composition which can exhibit an excellent bactericidal effect in the presence of an organic substance and against biofilms; a method for producing the bactericidal agent composition; and a sterilization method using the bactericidal agent composition. [Solution] A bactericidal agent composition which comprises water containing ultrafine bubbles having a most frequent particle diameter of 500 nm or less and a bactericidal component. Preferably, the density of most frequent particles of the ultrafine bubbles are 10,000 particles or more and the density of ultrafine bubbles each having a particle diameter of 1000 nm or less is 1,000,000 particles or more.

Abstract: A resonator is connected to a first plane which is one of a power plane and a ground plane, wherein the power plane and the ground plane are apart from each other in an up-down direction. The resonator comprises a connecting portion and a body portion. The connecting portion is connected to the first plane. The connecting portion extends in the up-down direction beyond a second plane, which is a remaining one of the power plane and the ground plane, while not being in electrical contact with the second plane. The body portion is connected to the connecting portion while not being in contact with the second plane. The body portion is arranged so that the second plane is located between the body portion and the first plane in the up-down direction.

Abstract: A medical resin composition is produced by mixing a powder of a polymer (A) comprising repeating units having an ester group and a liquid of a vinyl ester monomer (B) having 6 or more carbon atoms to increase a viscosity and, according to demand, further performing a polymerization reaction. The thus produced resin composition inhibits leaching of irritative substances, reduces any adverse effects on the human body by endocrine disruptors, etc. and can be prepared with high operational efficiency. The resin composition is suitably used as a dental resin composition such as a tissue conditioner, a functional impression material, a lining material, a denture base material or a mouth piece material.

Abstract: Provided is a detection kit for detecting target genes of miRNA. Also provided is a method of detecting target genes of miRNA in a simple manner without the need for performing a transfection operation of a gene into cells via a vector. The detection kit is a detection kit for target genes of microRNA, including a cell extraction reagent, and a labeling reagent for microRNA or labeled microRNA, and further including a reaction reagent for the labeling substance for microRNA. mRNA corresponding to target genes of miRNA can be easily pulled down by producing a cell extract under mild conditions, adding labeled miRNA to the cell extract, and recovering the labeling substance. cDNA is produced from the pulled down mRNA to detect target genes of miRNA.